Algeria
Egypt
Israel
Jordan
Lebanon
Libya
Morocco
Palestine *
Syria *
TunisiaCoronavirus: Commission unveils EU vaccines strategy
The European Commission presented on 17 June a European strategy to accelerate the development, manufacturing and deployment of vaccines against COVID-19.
With this strategy, the Commission will support efforts to accelerate the development and availability of safe and effective vaccines in a timeframe between 12 and 18 months, if not earlier. Delivering on this complex undertaking requires running clinical trials in parallel with investing in production capacity to be able to produce millions, or even billions, of doses of a successful vaccine. The Commission is fully mobilised to support the efforts of vaccine developers in their endeavour.
The European Commission is committed to the principle of universal, equitable and affordable access to vaccines, especially for the most vulnerable countries. It is ready to explore with international partners if a significant number of countries would agree to pool resources for jointly reserving future vaccines from companies for themselves as well as for low and middle-income countries at the same time. The high-income countries could act as an inclusive international buyers’ group, thus accelerating the development of safe and effective vaccines and maximise access to them for all who need it across the world.
Read more
President von der Leyen’s video message
Communication on the EU Strategy for COVID-19 vaccines
Countries covered:
-
Algeria
-
Egypt
-
Israel
-
Jordan
-
Lebanon
-
Libya
-
Morocco
-
Palestine *
-
Syria *
-
Tunisia
